Latest Patheon Inc (PNHNF) Headlines Patheon
Post# of 3
Posted On: 03/11/2014 12:56:06 AM
Latest Patheon Inc (PNHNF) Headlines
Patheon Inc. announces final court approval of arrangement
PR Newswire - Mon Mar 10, 11:17AM CDT
Patheon Inc. (TSX: PTI) ("Patheon") announced today that the Ontario Superior Court of Justice (Commercial List) (the "Court") has issued a final order approving Patheon's previously announced statutory plan of arrangement (the "Arrangement") under the Canada Business Corporations Act ("CBCA") pursuant to which JLL/Delta Patheon Holdings, L.P. ("Newco"), which is sponsored by an entity controlled by an affiliate of JLL Partners Inc. and Koninklijke DSM N.V., will indirectly acquire all of the issued and outstanding restricted voting shares of Patheon. In issuing the final order, the Court has determined that the Arrangement is fair and reasonable in accordance with the requirements of the CBCA.
Global Life Sciences BPO Market Market Forecasts & Opportunities, 2019
M2 - Mon Mar 10, 9:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gh67xx/life_sciences_bpo) has announced the addition of the "Global Life Sciences BPO Market Market Forecasts & Opportunities, 2019" report to their offering. The life sciences BPO market comprises services offered by Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) to the biotech pharmaceutical companies. A rise in demand for low cost drugs, patent expirations and uncertain economic conditions have compelled the pharmaceutical players to take support of various outsourcing services. This support has facilitated pharma players to streamline their value chain and focus more on its core strategies. Pharmaceutical companies are now forming long term partnership with the CROs and CMOs to share the costs involved in drug discovery to post marketing approvals. Moreover, they are also leveraging CROs and CMOs expertise such as use of novel technologies, trained staff and previous experiences for effective outcomes. The research report on life sciences BPO provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of life sciences BPO on the basis of different CRO and CMO services. The CRO services comprises clinical data management, monitoring, medical writing, regulatory services, pharmacovigilance, bio-statistics, drug discovery and pre-clinical tests. The CMO services include API manufacturing, Finished Dosage Formulation development and manufacturing and Packaging. The global life sciences BPO market has been segmented based on all the above- mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in terms of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global life sciences BPO market.The section also covers opportunities, market attractiveness analysis and Porter's Five Forces analysis for the market participants. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Life Sciences BPO Market Dynamics Chapter 4 Global Life Sciences BPO Market, by Segments Chapter 5 Global Life Sciences BPO Market, by Geography Chapter 6 Global Life Sciences BPO Market Share Analysis Chapter 7 Recommendations Chapter 8 Company Profiles - Accenture, Plc - Boehringer Ingelheim GmbH - Catalent Pharma Solutions, Inc. - Charles River Laboratories International, Inc. (CRL) - Cognizant Technology Solutions - Covance, Inc. - DSM - Fareva - ICON, Plc - Infosys - International Business Machines Corporation - Lonza Group - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Parexel International Corporation - Patheon, Inc. - Piramal Healthcare - PRA International, Inc. - Quintiles Transnational Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/gh...iences_bpo
Patheon shareholders approve plan of arrangement
PR Newswire - Thu Mar 06, 11:21AM CST
Patheon Inc. (TSX: PTI) ("Patheon") today announced that at a special meeting (the "Special Meeting") of holders of its restricted voting shares ("Shareholders") held earlier today, Shareholders passed a special resolution (the "Arrangement Resolution") approving a statutory plan of arrangement (the "Arrangement") under the Canada Business Corporations Act (the "CBCA") pursuant to which JLL/Delta Patheon Holdings, L.P. ("Newco") will indirectly acquire all of the issued and outstanding restricted voting shares of Patheon. Newco is sponsored by an entity controlled by JLL Partners, Inc. ("JLL") and Koninklijke DSM N.V.
Patheon Reports Preliminary Unaudited First Quarter Fiscal 2014 Results
PR Newswire - Thu Mar 06, 6:30AM CST
Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, with recently acquired proprietary products, announced today preliminary unaudited fiscal 2014 first-quarter results. Based on its current expectations, Patheon anticipates the following results for its first-quarter ended January 31, 2014:
Patheon to Attend DCAT Week
Marketwire - Thu Feb 27, 8:02AM CST
Patheon Inc., a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, will participate at DCAT Week in New York, N.Y., March 10-13, 2014. During DCAT Week, Patheon will participate in high-level strategic meetings with customers and suppliers.
Leading independent advisory firm ISS Recommends In Favour of the Arrangement Involving Patheon Inc.
PR Newswire - Tue Feb 25, 6:57PM CST
Patheon Inc. (TSX
TI) ("Patheon" or the "Company") announces that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm that provides advice and voting recommendations to shareholders, has published a report recommending that its subscribers vote "FOR" the resolution approving the statutory plan of arrangement under the Canada Business Corporations Act (the "Arrangement") that would effect a going private transaction for Patheon. On the closing of the proposed Arrangement, which was originally announced on November 19, 2013, JLL/Delta Patheon Holdings, L.P. ("Newco") will acquire, directly or indirectly, all of the restricted voting shares of Patheon at a cash price of US$9.32 per restricted voting share. Newco is sponsored by an entity controlled by JLL Partners, Inc. and Koninklijke DSM N.V.
Patheon Inc. Files Proxy Statement for Special Meeting of Shareholders
PR Newswire - Tue Feb 04, 4:35PM CST
Patheon Inc. (TSX TI) ("Patheon" or the "Company") announces that it has filed its definitive proxy statement and management information circular (the "Proxy Statement") with Canadian and U.S. securities regulators in connection with a special meeting of holders of restricted voting shares (the "Special Meeting") to be held to consider, and if deemed appropriate, to approve, among other things, a statutory plan of arrangement under the Canada Business Corporations Act (the "Arrangement") that would effect a going private transaction. The Proxy Statement will also be mailed to Patheon's shareholders. On the closing of the proposed Arrangement, which was originally announced on November 19, 2013, JLL/Delta Patheon Holdings, L.P. ("Newco") will acquire, directly or indirectly, all of the restricted voting shares of Patheon. Newco is sponsored by an entity controlled by JLL Partners, Inc. and Koninklijke DSM N.V.
Patheon to Showcase Late-Stage API Development Capabilities at InformEx
Marketwire - Thu Jan 16, 8:01AM CST
Patheon Inc., a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, will showcase its late-stage API development capabilities at InformEx in Miami, Fla., January 21-24, 2014.
JLL/Delta Dutch Newco B.V. Announces Offering of $500 Million Senior Notes due 2022
PR Newswire - Thu Jan 16, 7:15AM CST
JLL/Delta Dutch Newco B.V. (the "Company") announced today the commencement of a private offering of $500 million aggregate principal amount of its Senior Notes due 2022 (the "Notes"). The Company intends to use the net proceeds from the offering of the Notes as part of its financing for its previously-announced transactions pursuant to which the Company has agreed to acquire the outstanding equity securities of Patheon Inc. (TSX: PTI) and the pharmaceutical products business of Koninklijke DSM N.V. (the "Acquisitions"). It is expected that the proceeds of the offering will be deposited in escrow subject to the completion of the Acquisitions and satisfaction other customary conditions. Upon consummation of the Acquisitions, the Notes will be guaranteed, jointly and severally, by the Company's existing and future subsidiaries that are guarantors under the Company's senior secured credit facilities that will be entered into in connection with the financing of the Acquisitions.
Patheon reports fiscal 2013 results
PR Newswire - Fri Jan 10, 7:15PM CST
Top-line growth at 36.6 percent
SOCMA Welcomes Introduction of Bipartisan Trade Promotion Authority Legislation
PR Newswire - Thu Jan 09, 3:20PM CST
TPA a Critical Tool to Support Job Growth in Specialty Chemical Industry
RLI CorporationCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 8:05PM CST
Patheon Inc. (TSX: PTI) ("Patheon" or the "Company") today reminded holders of its restricted voting shares that the Company's current rights offering will expire in 10 days, on December 28, 2012. Rights certificates were mailed on December 3, 2012 to each registered holder of restricted voting shares resident in Canada and the U.S. as of November 27, 2012.
Meritor WABCO Enhances OnLane, its Innovative Lane Departure Warning System; New Video-Capturing Safety Feature Now Available
PR Newswire - Thu Dec 19, 3:17PM CST
Meritor WABCO, a leader in the integration of safety and efficiency technology for the North American commercial vehicle industry, today announced a new option for OnLane(TM), its innovative lane departure warning system, that enhances OnLane with the ability to record and save videos of critical safety events. The new video safety option is available now.
Dundee International REIT December 2013 monthly distribution
CNW Group - Wed Dec 18, 10:40AM CST
DUNDEE INTERNATIONAL REIT (TSX: DI.UN) today announced its December 2013 monthly distribution in the amount of 6.667 cents per unit (80 cents annualized). The December distribution will be payable on January 15, 2014 to unitholders of record as at December 31, 2013.
Media Advisory - Member of Parliament Gerald Keddy to Announce Support Arts and Culture in Nova Scotia's South Shore
CNW Group - Wed Dec 18, 8:00AM CST
Gerald Keddy, Parliamentary Secretary to the Minister of National Revenue and for the Atlantic Canada Opportunities Agency and Member of Parliament (South Shore?St. Margaret's), on behalf of the Honourable Shelly Glover, Minister of Canadian Heritage and Official Languages, will announce support for arts and culture in the South Shore on Thursday.
Mylan Announces Settlement Agreement for First-to-File Generic Version of TARGRETIN®
PR Newswire - Tue Dec 17, 1:31PM CST
Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. (a wholly-owned subsidiary of Patheon Inc.), have entered into a settlement and license agreement with Eisai Inc. and Valeant Pharmaceuticals Luxembourg S.a.r.l that will resolve patent litigation related to Bexarotene Capsules, 75 mg. Bexarotene is the generic version of TARGRETIN®, which is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.
Patheon Reports Preliminary Unaudited Full-Year Fiscal 2013 Results
PR Newswire - Tue Dec 03, 6:00AM CST
Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, with recently acquired proprietary products, announced today preliminary unaudited fiscal 2013 full-year results. Based on its current expectations, Patheon anticipates the following results for its fiscal year ended October 31, 2013:
Patheon Inc. to be Taken Private for US$9.32 per Share in Cash
PR Newswire - Mon Nov 18, 11:26PM CST
Independent Committee Unanimously Recommends Transaction
Patheon Inc. announces final court approval of arrangement
PR Newswire - Mon Mar 10, 11:17AM CDT
Patheon Inc. (TSX: PTI) ("Patheon") announced today that the Ontario Superior Court of Justice (Commercial List) (the "Court") has issued a final order approving Patheon's previously announced statutory plan of arrangement (the "Arrangement") under the Canada Business Corporations Act ("CBCA") pursuant to which JLL/Delta Patheon Holdings, L.P. ("Newco"), which is sponsored by an entity controlled by an affiliate of JLL Partners Inc. and Koninklijke DSM N.V., will indirectly acquire all of the issued and outstanding restricted voting shares of Patheon. In issuing the final order, the Court has determined that the Arrangement is fair and reasonable in accordance with the requirements of the CBCA.
Global Life Sciences BPO Market Market Forecasts & Opportunities, 2019
M2 - Mon Mar 10, 9:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gh67xx/life_sciences_bpo) has announced the addition of the "Global Life Sciences BPO Market Market Forecasts & Opportunities, 2019" report to their offering. The life sciences BPO market comprises services offered by Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) to the biotech pharmaceutical companies. A rise in demand for low cost drugs, patent expirations and uncertain economic conditions have compelled the pharmaceutical players to take support of various outsourcing services. This support has facilitated pharma players to streamline their value chain and focus more on its core strategies. Pharmaceutical companies are now forming long term partnership with the CROs and CMOs to share the costs involved in drug discovery to post marketing approvals. Moreover, they are also leveraging CROs and CMOs expertise such as use of novel technologies, trained staff and previous experiences for effective outcomes. The research report on life sciences BPO provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of life sciences BPO on the basis of different CRO and CMO services. The CRO services comprises clinical data management, monitoring, medical writing, regulatory services, pharmacovigilance, bio-statistics, drug discovery and pre-clinical tests. The CMO services include API manufacturing, Finished Dosage Formulation development and manufacturing and Packaging. The global life sciences BPO market has been segmented based on all the above- mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in terms of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global life sciences BPO market.The section also covers opportunities, market attractiveness analysis and Porter's Five Forces analysis for the market participants. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Life Sciences BPO Market Dynamics Chapter 4 Global Life Sciences BPO Market, by Segments Chapter 5 Global Life Sciences BPO Market, by Geography Chapter 6 Global Life Sciences BPO Market Share Analysis Chapter 7 Recommendations Chapter 8 Company Profiles - Accenture, Plc - Boehringer Ingelheim GmbH - Catalent Pharma Solutions, Inc. - Charles River Laboratories International, Inc. (CRL) - Cognizant Technology Solutions - Covance, Inc. - DSM - Fareva - ICON, Plc - Infosys - International Business Machines Corporation - Lonza Group - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Parexel International Corporation - Patheon, Inc. - Piramal Healthcare - PRA International, Inc. - Quintiles Transnational Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/gh...iences_bpo
Patheon shareholders approve plan of arrangement
PR Newswire - Thu Mar 06, 11:21AM CST
Patheon Inc. (TSX: PTI) ("Patheon") today announced that at a special meeting (the "Special Meeting") of holders of its restricted voting shares ("Shareholders") held earlier today, Shareholders passed a special resolution (the "Arrangement Resolution") approving a statutory plan of arrangement (the "Arrangement") under the Canada Business Corporations Act (the "CBCA") pursuant to which JLL/Delta Patheon Holdings, L.P. ("Newco") will indirectly acquire all of the issued and outstanding restricted voting shares of Patheon. Newco is sponsored by an entity controlled by JLL Partners, Inc. ("JLL") and Koninklijke DSM N.V.
Patheon Reports Preliminary Unaudited First Quarter Fiscal 2014 Results
PR Newswire - Thu Mar 06, 6:30AM CST
Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, with recently acquired proprietary products, announced today preliminary unaudited fiscal 2014 first-quarter results. Based on its current expectations, Patheon anticipates the following results for its first-quarter ended January 31, 2014:
Patheon to Attend DCAT Week
Marketwire - Thu Feb 27, 8:02AM CST
Patheon Inc., a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, will participate at DCAT Week in New York, N.Y., March 10-13, 2014. During DCAT Week, Patheon will participate in high-level strategic meetings with customers and suppliers.
Leading independent advisory firm ISS Recommends In Favour of the Arrangement Involving Patheon Inc.
PR Newswire - Tue Feb 25, 6:57PM CST
Patheon Inc. (TSX
TI) ("Patheon" or the "Company") announces that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm that provides advice and voting recommendations to shareholders, has published a report recommending that its subscribers vote "FOR" the resolution approving the statutory plan of arrangement under the Canada Business Corporations Act (the "Arrangement") that would effect a going private transaction for Patheon. On the closing of the proposed Arrangement, which was originally announced on November 19, 2013, JLL/Delta Patheon Holdings, L.P. ("Newco") will acquire, directly or indirectly, all of the restricted voting shares of Patheon at a cash price of US$9.32 per restricted voting share. Newco is sponsored by an entity controlled by JLL Partners, Inc. and Koninklijke DSM N.V. Patheon Inc. Files Proxy Statement for Special Meeting of Shareholders
PR Newswire - Tue Feb 04, 4:35PM CST
Patheon Inc. (TSX
TI) ("Patheon" or the "Company") announces that it has filed its definitive proxy statement and management information circular (the "Proxy Statement") with Canadian and U.S. securities regulators in connection with a special meeting of holders of restricted voting shares (the "Special Meeting") to be held to consider, and if deemed appropriate, to approve, among other things, a statutory plan of arrangement under the Canada Business Corporations Act (the "Arrangement") that would effect a going private transaction. The Proxy Statement will also be mailed to Patheon's shareholders. On the closing of the proposed Arrangement, which was originally announced on November 19, 2013, JLL/Delta Patheon Holdings, L.P. ("Newco") will acquire, directly or indirectly, all of the restricted voting shares of Patheon. Newco is sponsored by an entity controlled by JLL Partners, Inc. and Koninklijke DSM N.V. Patheon to Showcase Late-Stage API Development Capabilities at InformEx
Marketwire - Thu Jan 16, 8:01AM CST
Patheon Inc., a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, will showcase its late-stage API development capabilities at InformEx in Miami, Fla., January 21-24, 2014.
JLL/Delta Dutch Newco B.V. Announces Offering of $500 Million Senior Notes due 2022
PR Newswire - Thu Jan 16, 7:15AM CST
JLL/Delta Dutch Newco B.V. (the "Company") announced today the commencement of a private offering of $500 million aggregate principal amount of its Senior Notes due 2022 (the "Notes"). The Company intends to use the net proceeds from the offering of the Notes as part of its financing for its previously-announced transactions pursuant to which the Company has agreed to acquire the outstanding equity securities of Patheon Inc. (TSX: PTI) and the pharmaceutical products business of Koninklijke DSM N.V. (the "Acquisitions"). It is expected that the proceeds of the offering will be deposited in escrow subject to the completion of the Acquisitions and satisfaction other customary conditions. Upon consummation of the Acquisitions, the Notes will be guaranteed, jointly and severally, by the Company's existing and future subsidiaries that are guarantors under the Company's senior secured credit facilities that will be entered into in connection with the financing of the Acquisitions.
Patheon reports fiscal 2013 results
PR Newswire - Fri Jan 10, 7:15PM CST
Top-line growth at 36.6 percent
SOCMA Welcomes Introduction of Bipartisan Trade Promotion Authority Legislation
PR Newswire - Thu Jan 09, 3:20PM CST
TPA a Critical Tool to Support Job Growth in Specialty Chemical Industry
RLI CorporationCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 8:05PM CST
Patheon Inc. (TSX: PTI) ("Patheon" or the "Company") today reminded holders of its restricted voting shares that the Company's current rights offering will expire in 10 days, on December 28, 2012. Rights certificates were mailed on December 3, 2012 to each registered holder of restricted voting shares resident in Canada and the U.S. as of November 27, 2012.
Meritor WABCO Enhances OnLane, its Innovative Lane Departure Warning System; New Video-Capturing Safety Feature Now Available
PR Newswire - Thu Dec 19, 3:17PM CST
Meritor WABCO, a leader in the integration of safety and efficiency technology for the North American commercial vehicle industry, today announced a new option for OnLane(TM), its innovative lane departure warning system, that enhances OnLane with the ability to record and save videos of critical safety events. The new video safety option is available now.
Dundee International REIT December 2013 monthly distribution
CNW Group - Wed Dec 18, 10:40AM CST
DUNDEE INTERNATIONAL REIT (TSX: DI.UN) today announced its December 2013 monthly distribution in the amount of 6.667 cents per unit (80 cents annualized). The December distribution will be payable on January 15, 2014 to unitholders of record as at December 31, 2013.
Media Advisory - Member of Parliament Gerald Keddy to Announce Support Arts and Culture in Nova Scotia's South Shore
CNW Group - Wed Dec 18, 8:00AM CST
Gerald Keddy, Parliamentary Secretary to the Minister of National Revenue and for the Atlantic Canada Opportunities Agency and Member of Parliament (South Shore?St. Margaret's), on behalf of the Honourable Shelly Glover, Minister of Canadian Heritage and Official Languages, will announce support for arts and culture in the South Shore on Thursday.
Mylan Announces Settlement Agreement for First-to-File Generic Version of TARGRETIN®
PR Newswire - Tue Dec 17, 1:31PM CST
Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. (a wholly-owned subsidiary of Patheon Inc.), have entered into a settlement and license agreement with Eisai Inc. and Valeant Pharmaceuticals Luxembourg S.a.r.l that will resolve patent litigation related to Bexarotene Capsules, 75 mg. Bexarotene is the generic version of TARGRETIN®, which is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.
Patheon Reports Preliminary Unaudited Full-Year Fiscal 2013 Results
PR Newswire - Tue Dec 03, 6:00AM CST
Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, with recently acquired proprietary products, announced today preliminary unaudited fiscal 2013 full-year results. Based on its current expectations, Patheon anticipates the following results for its fiscal year ended October 31, 2013:
Patheon Inc. to be Taken Private for US$9.32 per Share in Cash
PR Newswire - Mon Nov 18, 11:26PM CST
Independent Committee Unanimously Recommends Transaction
(0)
(0)Patheon Inc (PNHNF) Stock Research Links
Scroll down for more posts ▼